Chairman and CEO, Omeros Corporation
Appears in 1 story
Leading company through first commercial launch
For decades, patients who developed transplant-associated thrombotic microangiopathy (TA-TMA) after stem cell transplants faced a grim reality: a life-threatening complication with no approved treatment. Mortality rates for high-risk cases reached 80-90%. In December 2025, the FDA approved Yartemlea, the first therapy for this condition, marking Seattle-based Omeros Corporation's first drug approval after 31 years. The company launched commercially on January 2, 2026, announced pricing at $36,000 per vial on January 7, and by late January both adult and pediatric patients were receiving treatment at transplant centers nationwide.
Updated Jan 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
